6 patients with Crohn's disease for 1-14 years have been treated with plasmapheresis for periods of up to 6 months. The symptoms of the one newly diagnosed patient were controlled by plasmapheresis alone, and 5 steroid-dependent patients were able to reduce their steroid requirements. During the study period, 13 clinical relapses were managed without increasing steroid dosage. There was evidence of circulating soluble immune complexes in all the patients and these levels were lowered by plasmapheresis. A possible role of plasmapheresis in the management of Crohn's disease is discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000198344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Surgery for Patients With Ileal Crohn's Disease.
Gastroenterol Hepatol (N Y)
November 2024
Professor of Gastroenterology Chair of the Department of Gastroenterology and Hepatology Amsterdam University Medical Centers Boelelaan, Amsterdam, The Netherlands.
A Severe Case of Disseminated Herpes Zoster in a Patient With Crohn's Disease on Upadacitinib Who Completed the Recombinant Zoster Vaccine Series.
ACG Case Rep J
February 2025
Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA.
Herpes zoster (HZ) is caused by the reactivation of the varicella zoster virus and presents with painful vesicular lesions in a dermatomal distribution. Disseminated HZ occurs when skin lesions erupt in numerous dermatomes. Upadacitinib is the first oral medication approved to treat moderate-severe Crohn's disease and has been associated with nonsevere cases of HZ.
View Article and Find Full Text PDFManagement of Overweight and Obesity in Patients With Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
December 2024
The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Increasing evidence has linked obesity to complications of inflammatory bowel disease (IBD); however, data are limited on the efficacy and impact of weight management strategies on the disease course. There are a strikingly limited number of interventional studies on weight management in patients with IBD, and the recent nutrition and IBD guidelines published in the United States do not mention weight management strategies. Overweight and obesity management in patients with IBD should follow a stepwise approach to assessment and treatment, including lifestyle modification, anti-obesity medications such as glucagon-like peptide-1 agonists, endobariatric procedures, and bariatric surgery (if deemed appropriate).
View Article and Find Full Text PDFFistula in Crohn's disease: classification, pathogenesis, and treatment options.
Tissue Barriers
January 2025
Department of Gastroenterology and Hepatology, Virginia Tech Carilion School of Medicine (VTCSOM), Carilion Clinic, Roanoke, VA, USA.
Crohn's disease is a form of inflammation that affects the gastrointestinal (GI) tract. It is characterized by persistent inflammation in the gut, which can lead to the formation of abnormal connections called fistulas. These fistulas can occur between the GI tract and the abdominal cavity, adjacent organs, or the skin.
View Article and Find Full Text PDFGenetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine.
Expert Rev Clin Immunol
January 2025
Division of Gastroenterology and Hepatology, Northwestern Medicine, Chicago, IL.
Introduction: Inflammatory bowel diseases (IBDs), comprised of ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory diseases of the gastrointestinal tract. Clinicians and patients must vigilantly manage these complex diseases over the course of the patient's lifetime to mitigate risks of the disease, surgical complications, progression to neoplasia, and complications from medical or surgical therapies. Over the past several decades, the armamentarium of IBD therapeutics has expanded; now with biologics and advanced small molecules complementing conventional drugs such as aminosalicylates, corticosteroids and thiopurines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!